KindredBio Revenue and Competitors
Estimated Revenue & Valuation
- KindredBio's estimated annual revenue is currently $19.7M per year.
- KindredBio received $46.0M in venture funding in January 2019.
- KindredBio's estimated revenue per employee is $155,000
- KindredBio's total funding is $62.1M.
Employee Data
- KindredBio has 127 Employees.
- KindredBio grew their employee count by -18% last year.
KindredBio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
2 | Senior Manager, Regulatory and Quality | Reveal Email/Phone |
KindredBio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is KindredBio?
Our goal is to save lives and relieve suffering for the animals in our lives. We bring a determination and dedication to unite our expertise and research creativity in developing humane, effective, and safe therapies for our animal companions that people enjoy today. We are veterinary therapeutics, redefined. As one of the first pet biotech companies in the world, we understood early that to quickly deliver veterinary therapeutics in unmet and under served areas we needed a revolutionary approach. By leveraging the similarities between human and pet diseases, we are creating cutting edge versions of successful human drugs and biologics. Our belief is that this can substantially increase success rate and reduce time to market - increasing the quality of life for the pets with whom we share so much of our lives, providing the veterinary community with innovative treatment options, and, we anticipate, generating solid returns for our investors.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$62.1M
Total Funding
127
Number of Employees
$19.7M
Revenue (est)
-18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
KindredBio News
GREENFIELD, Ind. and SAN FRANCISCO, June 16, 2021 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) and Kindred Biosciences, Inc. (KindredBio,NASDAQ: KIN) today announced the parties have entered into a definitive agreement for Elanco to acquire KindredBio, a biopharmaceutical com ...
SAN FRANCISCO, June 2, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030 in dogs infected by parvovirus. The primary endpoint wa ...
SAN FRANCISCO, May 11, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2021 and provided updates on its programs. For the first qua ...
As a cGMP pool contractor, KindredBio is eligible to provide manufacturing, formulation and analytical services to meet the needs of the ...
During this time, investors will have the opportunity to discuss recent developments, including the launch of KindredBio's first product, study ...
Other Companies in Burlingame
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $17.8M | 127 | 49% | $27.2M |
#2 | $15M | 134 | 6% | N/A |
#3 | $30.6M | 135 | 7% | $26M |
#4 | $34.3M | 137 | 47% | N/A |
#5 | $20.2M | 139 | N/A | N/A |
KindredBio Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-03-19 | $Undisclosed | Undisclosed | Leerink Partners LLC | Article |
| 2014-04-04 | $54.0M | Undisclosed | Leerink Partners LLC | Article |
| 2014-04-09 | $58.1M | Undisclosed | Leerink Partners LLC | Article |
| 2017-07-13 | $25.8M | Undisclosed | Ladenburg Thalmann & Co. Inc | Article |
| 2018-06-26 | $57.2M | Undisclosed | Cantor Fitzgerald & Co | Article |
| 2019-01-21 | $46.0M | Undisclosed | Barclays Capital Inc | Article |